Medtronic, Inc.

New Hope Research Foundation, Inc.

Other

Sigma Labs, Inc.

John G. Keimel

John G Keimel

Xiaoyi Min

Timothy G Laske

Mary M Morris

Terrell M Williams

Gregory A Boser

David L Thompson

Gregory John Haubrich

Warren L Starkebaum

Steven D Goedeke

Peter M Mulier

Timothy W Holleman

Gary L Lubben

Craig L Schmidt

Rahul Mehra

Angelo Yializis

William Frederick Kaemmerer

William G Howard

Peter M J Mulier

David K Peterson

Glenn M Roline

Richard D Sandstrom

Michael D Kaytor

John T Meador

Pat L Gordon

Girard B Borgerding

Joseph A Ballis

Roger E Rugland

Alvin S Rhorer

Terrell W Williams

Clare E Padgett

Trey William Huntoon

Thomas Kiekhafer

Fred Lindemans

Suribhotla V Rajasekhar

Michael David Kaytor

Aspects herein relate to systems and methods for delivery of biologic agents to the central nervous system. In various embodiments, a method of administering a therapeutic agent to the central nervous system (CNS) is included. The method can include injecting a therapeutic agent into a first cerebrospinal fluid (CSF) region of the subject. The method can further include establishing fluid communication between a fluid reservoir and a second cerebrospinal fluid (CSF) region of a subject, the fluid having a hydraulic pressure at or above an intracranial pressure. The method can further include infusing a hyperosmotic fluid systemically. Other embodiments, including kits and systems are also included herein.

Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord

Embodiments herein include polynucleotides, vectors and methods for the insertion and expression of transgenes. In an embodiment, a polynucleotide is included. The polynucleotide can include a JeT promoter or variant thereof, an intron sequence less than 400 bases in length, and a polynucleotide sequence encoding a polypeptide or protein operatively linked to the promoter. In an embodiment, a recombinant vector is included. The recombinant vector can include a JeT promoter or variant thereof, an intron sequence less than 400 bases in length, and a polynucleotide sequence encoding a polypeptide or protein operatively linked to the promoter. Other embodiments are also included herein.

Polynucleotides, vectors and methods for insertion and expression of transgenes

Techniques for delivering genetic material to a target tissue site of a patient via a leadless implantable medical device that includes a pump and a stimulation energy delivery element are described. In some examples, delivery of genetic material to the target tissue site causes transgene expression of tissue at the target tissue site, which may result in generation of new cells or modified properties of existing cells of the target tissue site, facilitating more effective and efficient treatment of a disorder of the patient.

Leadless implantable medical device with osmotic pump

The present invention is directed to systems and methods for delivering therapy for a cardiac disorder, wherein the system comprises a source for supplying a protein formulation containing a protein that is otherwise deficient in cardiac cells in a patient with a cardiac disorder, and a catheter having a proximal end and a distal end for delivering the protein formulation to the pericardial sac region of a human heart.

Method for treatment of cardiac disorders

Method and apparatus for treatment of cardiac disorders

Methods for delivering first and second fluid compositions to a target location of a subject include delivering the first composition from reservoir of an implantable infusion pump and delivering the second composition through a catheter access port of the implantable infusion device. The access port and reservoir are fluidly coupled to a catheter having a delivery region implanted in the target region. The methods more fully realize the therapeutic potential of infusion devices having both an access port and a reservoir. Strategic use of different agents that compliment the function of each other delivered via either the access port or the reservoir can result in enhanced therapeutic potential.

Methods for infusing fluids via an implantable infusion system

Techniques are described that allow an implantable device to sense gastric data and activity data from a patient, and estimate the patient's amount of energy consumed and energy expended based on the sensed data. A system provides feedback to the patient, a family member, or a doctor about the patient's energy consumed, energy expended, and net energy. The data may be provided in table or graphical format, and may show daily or weekly energy balance data or may show a trend of the daily or weekly energy data. The patient may receive feedback by an implanted alert module that provides and audio alert or a vibration alert. In addition, data acquired by the system may be used to adjust the patient's stimulation therapy parameters.

Energy balance therapy for obesity management

An improved implantable sensor system is disclosed that includes an array of sensors. Each of the sensors is associated with a protective member that prevents the sensor from interacting with the surrounding environment. At a selected time, the protective member may be disabled, thereby allowing the sensor to begin sensing signals within a living body. In one embodiment, the protective member is formed of a conductive material that can oxidize, is biocompatible, bio-absorbable, and that may be dissolved in solution such as blood upon application of an electric potential. In another embodiment, the protective member is formed of a dissolvable member that dissolves within the body over a predetermined time period.

Sensor system

An implantable medical device having a dual cell power source powering a high-power output circuit and a low-power control circuit. The power source includes a first, high-rate cell and a second, lower-rate cell having a rate capability less than a rate capability of the first, high-rate cell. The first and second cells are electrically connected to the output circuit and control circuit by circuitry. In one embodiment, the circuitry connects the first and second cells in parallel to the output circuit and the control circuit, and includes a switching circuit for selectively uncoupling the first, high-rate cell from the control circuit during a transient high power pulse. In another embodiment, the first and second cells are formed within a single case and are connected in parallel to the output circuit and the control circuit. In another embodiment, the high-rate cell is anode limited, characterized by a rate capability exhibiting minimal dependence on time up to a pre-selected voltage-based ERI at which at least 40 percent of the cathode is consumed.

Implantable medical device with dual cell power source

A system and method is provided to view an anatomical structure such as a blood vessel in high contrast with its surrounding tissue. The system and method may be used to produce an image of an anatomical structure using reflected electromagnetic radiation singularly scattered from target tissue. The system and method may also provide same-side illumination and detection of reflected electromagnetic radiation in a convenient integral imaging device. The system and method may also provide helmet mounted imaging technology in a single integral helmet which allows the wearer to view an anatomical structure located within a patient such that the image is continuously oriented according to the orientation of the helmet wearer's head. The system and method may also be used in the performance of venipuncture. The system and method may provide for improved contrast between any anatomical structure and its surrounding tissue for use in any imaging system.

Implantable device with automatic sensing adjustment

A lead and a lead system for dispersion of a cardioversion/defibrillation electrode formed of one or more small diameter defibrillation electrodes in a heart chamber and for attaching a pace/sense electrode in contact with the heart. The small diameter defibrillation electrode or electrodes extend distally from the distal end of the lead body. If multiple electrodes are employed, they are preferably biased to spread apart when unrestrained and have a cross-section size small enough to be inserted into interstices of trabeculae in the ventricular chamber. The distal ends of the defibrillation electrodes may be free of attachment to the lead body or may be attached by a weak bond to the distal portion of the lead.

Intracardiac defibrillation leads

An alternative mechanism in an implantable device for meeting the physician's need for a stored electrogram and/or other stored physiologic signal associated with a detected arrhythmic or other physiological event without the undesirable current drain associated with continuous operation of a sense amplifier and a looping memory. The device regularly but intermittently activates a sense amplifier or other sensor and associated memory circuitry, independent of detection of arrhythmias. The device may temporarily store only a single record, replacing it with new records as they are stored, or may store multiple records, replacing the oldest stored record with the newest stored record. On detection of an arrhythmia or other defined physiological event, the device may simply transfer the one or more temporarily stored electrogram strips to permanent storage, for later use by the physician in diagnosing the condition of the patient prior to detection of the event.

Method and apparatus for storage of physiologic signals

Implantable defibrillator and lead system

Growing community of inventors

North Oaks, MN, United States of America

John G Keimel